Biomarkers in the Diagnosis and Prognosis of Alzheimer’s Disease

Journal of Laboratory Automation

Volumn 20, Issue 5, 2015, Pages 589-600

  Schaffer, Cole ^a   Sarad, Nakia ^a   DeCrumpe, Ashton ^a   Goswami, Disha ^a   Herrmann, Sara ^a   Morales, Jose ^a   Patel, Parth ^a   Osborne, Jim ^a  

^a KECK GRADUATE INSTITUTE   (United States)

Author keywords

Alzheimer s disease; amyloid beta; biomarkers; CSF; diagnosis; early; ELISA; FDG; glucose; immunoassay; multiplex bead array; PET; tau

Indexed keywords

BIOMARKERS; BRAIN; CEREBROSPINAL FLUID; GLUCOSE; GLYCOPROTEINS; IMMUNOLOGY; NEURODEGENERATIVE DISEASES; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY;

ALZHEIMER; AMYLOID BETAS; EARLY; ELISA; IMMUNOASSAY;

DIAGNOSIS;

AMYLOID BETA PROTEIN; BRAIN PROTEIN; CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE; GLUCOSE; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; NEURONAL THREAD PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ASSAY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE FUNCTION TEST; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ANALYSIS; HUMAN; IMMUNOFLUORESCENCE ASSAY KIT; IMMUNOREACTIVITY; INTERVIEW; MILD COGNITIVE IMPAIRMENT; MULTIPLEX BEAD ARRAY ASSAY; NUCLEAR MAGNETIC RESONANCE IMAGING; ODOR RECOGNITION TEST; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS; ANIMAL; BLOOD; BRAIN; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; LABORATORY AUTOMATION; METABOLISM; NERVE CELL; NEUROIMAGING; PHOSPHORYLATION; PROTEIN PROCESSING; TRENDS; URINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOMATION, LABORATORY; BIOMARKERS; BRAIN; EARLY DIAGNOSIS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 84941902135     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068214559979     Document Type: Review

References (110)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. N. Engl. J. Med. 1994, 331, 1163–1166.
2. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures; Alzheimer’s Association: Los Angeles, 2013.
3. S.SorensenM.PinquartP.DubersteinHow Effective Are Interventions with Caregivers? An Updated Meta-Analysis. Gerontologist2002, 42, 356–372.
4. K.MaslowK.M.LangaM.U.Kabeto. Early-Onset Dementia: A National Challenge, A Future Crisis; Alzheimer’s Association: Los Angeles, 2006.
5. S.SeshadriA.BeiserM.Kelly-Hayes. The Lifetime Risk of Stroke: Estimates from the Furmingham Study. Stroke2006, 37, 345–350.
6. L.E.HebertJ.WeuveP.A.Scherr. Alzheimer Disease in the United States (2010-2050) Estimated Using the 2010 Census. Neurology2013, 80, 1778–1783.
7. D.ScheunerC.EckmanM.Jensen. Secreted Amyloid Beta-Protein Similar to That in the Senile Plaques of Alzheimer’s Disease Is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer’s Disease. Nat. Med. 1996, 2, 864–870.
8. C.A.LemereF.LoperaK.S.Kosik. The E280A Presenilin 1 Alzheimer Mutation Produces Increased A Beta 42 Deposition and Severe Cerebellar Pathology. Nat. Med. 1996, 2, 1146–1150.
9. R.J.BatemanE.R.SiemersK.G.Mawuenyega. A Gamma-Secretase Inhibitor Decreases Amyloid-Beta Production in the Central Nervous System. Ann. Neurol. 2009, 66, 48–54.
10. E.H.CorderA.M.SaundersW.J.Strittmatter. Gene Dose of Apolipoprotein-E Type-4 Allele and the Risk of Alzheimers-Disease in Late-Onset Families. Science1993, 261, 921–923.
11. L.A.FarrerL.A.CupplesJ.L.Haines. Effects of Age, Sex, and Ethnicity on the Association between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-Analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA1997, 278, 1349–1356.
12. L.BertramM.B.McQueenK.Mullin. Systematic Meta-Analyses of Alzheimer Disease Genetic Association Studies: The AlzGene Database. Nat. Genet. 2007, 39, 17–23.
13. J.KimJ.M.BasakD.M.HoltzmanThe Role of Apolipoprotein E in Alzheimer’s Disease. Neuron2009, 63, 287–303.
14. K.R.BrundenJ.Q.TrojanowskiV.M.LeeAdvances in Tau-Focused Drug Discovery for Alzheimer’s Disease and Related Tauopathies. Nat. Rev. Drug Discov. 2009, 8, 783–793.
15. B.ZhangA.MaitiS.Shively. Microtubule-Binding Drugs Offset Tau Sequestration by Stabilizing Microtubules and Reversing Fast Axonal Transport Deficits in a Tauopathy Model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 227–231.
16. T.IshiharaM.HongB.Zhang. Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform. Neuron1999, 24, 751–762.
17. C.CordellS.BorsonM.Boustani. Alzheimer’s Association Recommendations for Operationalizing the Detection of Cognitive Impairment during the Medicare Annual Wellness Visit in a Primary Care Setting. Alzheimers Dement. 2013, 9, 141–150.
18. S.BorsonJ.ScanlanM.Brush. The Mini-Cog: A Cognitive “Vital Signs” Measure for Dementia Screening in Multi-Lingual Elderly. Int. J. Geriatr. Psychiatry2000, 15, 1021–1027.
19. W.LorentzJ.ScanlanS.BorsonBrief Screening Tests for Dementia. Can. J. Psychiatry2002, 47, 723–733.
20. M.M.EhrenspergerM.BerresK.I.Taylor. Screening Properties of the German IQCODE with a Two-Year Time Frame in MCI and Early Alzheimer’s Disease. Int. Psychogeriatr. 2010, 22, 91–100.
21. W.ThiesL.BleilerAlzheimer’s Association Report: 2013 Alzheimer’s Disease Facts and Figures. Alzheimer Dement. 2013, 9, 208–245.
22. F.KierV.Molinari“Do-It-Yourself” Dementia Testing: Issues Regarding an Alzheimer’s Home Screening Test. Gerontologist2003, 43, 295–301.
23. M.D.ThompsonK.KneeC.J.GoldenOlfaction in Persons with Alzheimer’s Disease. Neuropsychol. Rev. 1998, 6, 11–23.
24. I.MundinanoM.HernandezC.DiCaudo. Reduced Cholinergic Olfactory Centrifugal Inputs in Patients with Neurodegenerative Disorders and MPTP-Treated Monkeys. Acta Neuropathol. 2013, 126, 411–425.
25. P.HauserThe Minnesota Cognitive Acuity Screen (MCAS): Valuable Predictor of Mortality. J. Acad. Life Underwrit. 2010, 26, 54–58.
26. D.KnopmanD.KnudsonM.Yoes. Development and Standardization of a New Telephonic Cognitive Screening Test: The Minnesota Cognitive Acuity Screen (MCAS). Neuropsychiatry Neuropsychol. Behav. Neurol. 2000, 13, 286–296.
27. K.JohnsonC.P.VegaACMG Issues New Guidelines for Genetic Testing in Alzheimer’s Disease. Medscape Educational Clinical Briefs, 2011.
28. R.Craig-SchapiroR.J.PerrinC.M.Roe. YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer’s Disease. Biol. Psychiatry2010, 68, 903–912.
29. F.NobiliS.Morbelli[18F]FDG-PET as a Biomarker for Early Alzheimer’s Disease. Open Nucl. Med. J. 2010, 2, 46–52.
30. L.M.BloudekE.D.SpackmanM.Blankenburg. Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer’s Disease. J. Alzheimers Dis. 2011, 26, 627–645.
31. O.HanssonH.ZetterbergP.Buchhave. Association between CSF Biomarkers and Incipient Alzheimer’s Disease in Patients with Mild Cognitive Impairment: A Follow-Up Study. Lancet Neurol. 2006, 5, 228–234.
32. C.ZhangNatural Compounds That Modulate BACE1-Processing of Amyloid-Beta Precursor Protein in Alzheimer’s Disease. Discov. Med. 2012, 14, 189–197.
33. K.G.MawuenyegaW.SigurdsonV.Ovod. Decreased Clearance of CNS Beta-Amyloid in Alzheimer’s Disease. Science2010, 330, 1774.
34. J.GotzF.ChenJ.van Dorpe. Formation of Neurofibrillary Tangles in P301l Tau Transgenic Mice Induced by Abeta 42 Fibrils. Science2001, 293, 1491–1495.
35. A.EckertS.HauptmannI.Scherping. Oligomeric and Fibrillar Species of Beta-Amyloid (A beta 42) Both Impair Mitochondrial Function in P301L Tau Transgenic Mice. J. Mol. Med. (Berl)2008, 86, 1255–1267.
36. C.BallatoreV.M.LeeJ.Q.TrojanowskiTau-Mediated Neurodegeneration in Alzheimer’s Disease and Related Disorders. Nat. Rev. Neurosci. 2007, 8, 663–672.
37. J.L.GuoV.M.LeeSeeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles. J. Biol. Chem. 2011, 286, 15317–15331.
38. R.J.PerrinR.Craig-SchapiroJ.P.Malone. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer’s Disease. PloS One2011, 6, 1–23.
39. F.A.BeltránA.I.AcuñaM.P.Miró. Brain Energy Metabolism in Health and Disease. Neuroscience: Dealing with Frontiers2012, 331-362.
40. K.ShahS.DeSilvaT.AbbruscatoThe Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer’s Disease. Int. J. Mol. Sci. 2012, 13, 12629–12655.
41. Z.ChenC.ZhongDecoding Alzheimer’s Disease from Perturbed Cerebral Glucose Metabolism: Implications for Diagnostic and Therapeutic Strategies. Prog. Neurobiol. 2013, 108, 21–43.
42. S.ArltS.BrassenH.Jahn. Association between FDG Uptake, CSF Biomarkers and Cognitive Performance in Patients with Probable Alzheimer’s Disease. Eur. J. Nucl. Med. Mol. Imaging2009, 36, 1090–1100.
43. S.Killion; Kinemed. Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls. 2013. In: ClinicalTrials.gov. Identifier: NCT01348061.
44. P.FanaraP.Y.WongK.H.Husted. Cerebrospinal Fluid–Based Kinetic Biomarkers of Axonal Transport in Monitoring Neurodegeneration. J. Clin. Invest. 2012, 122, 3159–3169.
45. S.PatelR.J.ShahP.Coleman. Potential Peripheral Biomarkers for the Diagnosis of Alzheimer’s Disease. Int. J. Alzheimers Dis. 2011, 2011, 1–9.
46. K.BlennowCerebrospinal Fluid Protein Biomarkers for Alzheimer’s Disease. NeuroRx2004, 1, 213–225.
47. A.LonneborgBiomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood. Mol. Diag. Ther. 2008, 12, 307–320.
48. Z.ChenC.ZhongDecoding Alzheimer’s Disease from Perturbed Cerebral Glucose Metabolism: Implications for Diagnostic and Therapeutic Strategies. Prog. Neurobiol. 2013, 108, 21–43.
49. L.S.SchneiderP.S.InselM.W.Weiner. Treatment with Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch. Neurol. 2011, 68, 58–66.
50. M.A.BuscheX.ChenH.A.Henning. Critical Role of Soluble Amyloid-Beta for Early Hippocampal Hyperactivity in a Mouse Model of Alzheimer’s Disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 8740–8745.
51. A.K.GhoshM.BrindisiJ.TangDeveloping ss-Secretase Inhibitors for Treatment of Alzheimer’s Disease. J. Neurochem. 2012, 120, 71–83.
52. B.P.ImbimboG.A.GiardinaGamma-Secretase Inhibitors and Modulators for the Treatment of Alzheimer’s Disease: Disappointments and Hopes. Curr. Top. Med. Chem. 2011, 11, 1555–1570.
53. P.H.ReddyR.TripathiQ.Troung. Abnormal Mitochondrial Dynamics and Synaptic Degeneration as Early Events in Alzheimer’s Disease: Implications to Mitochondria-Targeted Antioxidant Therapeutics. Biochim. Biophys. Acta2012, 1822, 639–649.
54. D.SchenkR.BarbourW.Dunn. Immunization with Amyloid-Beta Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse. Nature1999, 400, 173–177.
55. T.E.GoldeL.S.SchneiderE.H.KooAnti-Aβ Therapeutics in Alzheimer’s Disease: The Need for a Paradigm Shift. Neuron2011, 69, 203–213.
56. K.H.AsheK.R.ZahsProbing the Biology of Alzheimer’s Disease in Mice. Neuron2010, 66, 631–645.
57. Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease.” The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol. Aging1998, 19, 109–116.
58. R.BoellaardStandards for PET Image Acquisition and Quantitative Data Analysis. J. Nucl Med. 2009, 50, 11S–20S.
59. M.F.ElshalJ.P.McCoyMultiplex Bead Array Assays: Performance Evaluation and Comparison of Sensitivity to ELISA. Methods2006, 38, 317–323.
60. L.S.WangY.Y.LeungS.K.Chang. Comparison of xMAP and ELISA Assays for Detecting Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease. J. Alzheimers Dis. 2012, 31, 439–445.
61. N.SchoonenboomC.MulderH.Vanderstichele. Effects of Processing and Storage Conditions on Amyloid Beta (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. Clin. Chem. 2005, 51, 189–195.
62. J.KangH.VandersticheleJ.Q.Trojanowski. Simultaneous Analysis of Cerebrospinal Fluid Biomarkers Using Microsphere-Based xMAP Multiplex Technology for Early Detection of Alzheimer’s Disease. Methods2012, 56, 484–493.
63. xMAP Technology by Luminex: Flexible, Open-Architecture Design That Can Be Configured to Perform a Wide Variety of Bioassays. http://www.luminexcorp.com/TechnologiesScience/xMAPTechnology/.
64. xMAP Technology. http://www.ld.ru/multiplex/ilist-4286.html.
65. R.J.BatemanC.XiongT.L.S.Benzinger. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease. N. Engl. J. Med. 2012, 367, 795–804.
66. L.M.ShawH.VandersticheleM.Knapik-Czajka. Qualification of the Analytical and Clinical Performance of CSF Biomarker Analyses in ADNI. Acta Neuropathol. 2011, 121, 597–609.
67. K.BlennowH.HampelCSF Markers for Incipient Alzheimer’s Disease. Lancet Neurol. 2003, 2, 605–613.
68. C.HumpelIdentifying and Validating Biomarkers for Alzheimer’s Disease. Trends Biotechnol. 2011, 29, 26–32.
69. N.MattssonH.ZetterbergO.Hansson. CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment. JAMA2009, 302, 385–393.
70. E.M.ReimanW.J.JagustBrain Imaging in the Study of Alzheimer’s Disease. Neuroimage2012, 61, 505–516.
71. V.PrashanthiJ.CliffordRole of Structural MRI in Alzheimer’s Disease. Alzheimers Res. Ther. 2010, 2, 23–33.
72. C.R.JackJr.H.J.WisteP.Vemuri. Brain Beta-Amyloid Measures and Magnetic Resonance Imaging Atrophy Both Predict Time-to-Progression from Mild Cognitive Impairment to Alzheimer’s Disease. Brain2010, 133, 3336–3348.
73. Health Quality Ontario. Functional Brain Imaging: An Evidence-Based Analysis. Ontario Health Technol. Assess. Ser. 2006, 6, 1–79.
74. S.L.RisacherA.J.SaykinNeuroimaging and Other Biomarkers for Alzheimer’s Disease: The Changing Landscape of Early Detection. Annu. Rev. Clin. Psychol. 2013, 9, 621–648.
75. Z.WangC.YanC.Zhao. Spatial Patterns of Intrinsic Brain Activity in Mild Cognitive Impairment and Alzheimer’s Disease: A Resting-State Functional MRI Study. Hum. Brain Mapp. 2011, 32, 1720–1740.
76. A.MeenaA Study of Functional Brain Metabolism Using PET Scan Image Datasets: An Analysis. J. Comput. 2013, 6, 28–30.
77. I.VerelG.VisserG.Van DongenThe Promise of Immuno-PET in Radioimmunotherapy. J. Nucl. Med. 2005, 46, 164S–171S.
78. M.N.LonsdaleT.BeyerDual-Modality PET/CT Instrumentation: Today and Tomorrow. Eur. J. Radiol. 2010, 73, 452–460.
79. University of Utah Health Sciences. Brain Imaging Technologies. http://learn.genetics.utah.edu/content/addiction/brainimaging/.
80. W.J.JagustD.BandyK.Chen. The ANDI PET Core. Alzheimers Dement. 2010, 6, 221–229.
81. H.VandersticheleG.De MeyerF.Shapiro. BioMarkers for Early Diagnosis of Alzheimer’s Disease; Nova Science Publishers: Hauppauge, NY, 2008.
82. N.GillingsRadiotracers for Positron Emission Tomography Imaging. Magn. Reson. Mater. Phys. Biol. Med. 2013, 26, 149–158.
83. P.B.VergheseJ.M.CastellanoD.M.HoltzmanApolipoprotein E in Alzheimer’s Disease and Other Neurological Disorders. Lancet Neurol. 2011, 10, 241–252.
84. J.M.LongD.K.LahiriMicroRNA-101 Downregulates Alzheimer’s Amyloid-Beta Precursor Protein Levels in Human Cell Cultures and Is Differentially Expressed. Biochem. Biophys. Res. Commun. 2011, 404, 889–895.
85. J.Nunez-IglesiasC.LiuT.E.Morgan. Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer’s Disease Cortex Reveals Altered miRNA Regulation. Plos One2010, 5, e8898.
86. S.S.HebertK.HorreL.Nicolai. Loss of MicroRNA Cluster miR-29a/b-1 in Sporadic Alzheimer’s Disease Correlates with Increased BACE1/Beta-Secretase Expression. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 6415–6420.
87. N.MattssonE.RosenO.Hansson. Age and Diagnostic Performance of Alzheimer Disease CSF Biomarkers. Neurology2012, 78, 468–476.
88. C.SchmidtM.WolffM.Weitz. Rapidly Progressive Alzheimer Disease. Arch. Neurol. 2011, 68, 1124–1130.
89. P.BuchhaveK.BlennowH.Zetterberg. Longitudinal Study of CSF Biomarkers in Patients with Alzheimer’s Disease. PLoS One2009, 4, e6294.
90. E.StomrudO.HanssonH.Zetterberg. Correlation of Longitudinal Cerebrospinal Fluid Biomarkers with Cognitive Decline in Healthy Older Adults. Arch. Neurol. 2010, 67, 217–223.
91. A.HaldenwangerP.ElingA.Kastrup. Correlation between Cognitive Impairment and CSF Biomarkers in Amnesic MCI, Non-Amnesic MCI, and Alzheimer’s Disease. J. Alzheimers Dis. 2010, 22, 971–980.
92. H.HampelS.TeipelT.Fuchsberger. Value of CSF Beta-Amyloid(1-42) and Tau as Predictors of Alzheimer’s Disease in Patients with Mild Cognitive Impairment. Mol. Psychiatry2004, 9, 705–710.
93. J.D.DoeckeS.M.LawsN.G.Faux. Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Arch. Neurol. 2012, 69, 1318–1325.
94. C.LaskeT.LeyheE.Stransky. Identification of a Blood-Based Biomarker Panel for Classification of Alzheimer’s Disease. Int. J. Neuropsychopharmacol. 2011, 14, 1147–1155.
95. J.K.LuiS.M.LawsQ.X.Li. Plasma Amyloid-Beta as a Biomarker in Alzheimer’s Disease: The AIBL Study of Aging. J. Alzheimers Dis. 2010, 20, 1233–1242.
96. M.W.Kieran; Dana-Farber Cancer Institute. A-Protein Levels in Adult and Pediatric Brain Tumor Patients. 2007. In: ClinicalTrials.gov. Identifier: NCT00165542.
97. R.Craig-SchapiroM.KuhnC.Xiong. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer’s Disease Diagnosis and Prognosis. PLoS One2011, 6, e18850.
98. S.M.LandauD.HarveyC.M.Madison. Comparing Predictors of Conversion and Decline in Mild Cognitive Impairment. Neurology2010, 75, 230–238.
99. P.BeurdeleyR.EinsteinW.ZhouProcessus et procedes de diagnostic de la maladie d’alzheimer. Patent CA2768339 A1, February3, 2011.
100. Innogenetics INNO-BIA AlzBio3. http://search.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/IGT_/80584.20090219.pdf.
101. C.ChenD.A.RidzonA.J.Broomer. Real-Time Quantification of MicroRNAs by Stem-Loop RT-PCR. Nucleic Acids Res. 2005, 33, e179.
102. W.F.GoureR.C.GasparA.Mccampbell. Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers. U.S. Patent WO2013009703 A2, January17, 2013.
103. R.NitschAnticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations. Patent EP2527369 A2, November28, 2012.
104. I.KazutomoI.KoichiP.Jun-Mi. Antiphosphorylated Tau Protein Antibody and Method for Detecting Alzheimer’s Disease with the Use of the Same. U.S. Patent WO1997034145 A1, September18, 1997.
105. E.M.MandelkowE.MandelkowB.Lichtenberg-Kraag. Tools for the Diagnosis and Treatment of Alzheimer’s Disease. U.S. Patent WO1993011231 A1, June10, 1993.
106. D.V.Andre VanM.VandermeerenE.VanmechelenMonoclonal Antibodies Specific for phf-tau, Hybridomas Secreting Them, Antigen Recognition by These Antibodies and Their Applications. U.S. Patent WO1995017429 A1, June29, 1995.
107. K.UrakamiM.KimuraDiagnostic Kit for Alzheimer’s Disease, Diagnostic Marker, and Detection Method for Indicator of Pathological State Thereof. U.S. Patent US8105839 B2, January331, 2012.
108. Centers for Medicare & Medicaid Services. FDA CLIA Overview. http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia/.
109. E.M.BurdValidation of Laboratory-Developed Molecular Assays for Infectious Diseases. Clin. Microbiol. Rev. 2010, 23, 550–576.
110. U.S. Food and Drug Administration. Clinical Laboratory Improvements Amendment (CLIA). http://www.fda.gov/medicaldevices/deviceregulationandguidance/ivdregulatoryassistance/ucm124105.htm.